Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells.

Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S.

Blood. 2005 Aug 15;106(4):1382-91. Epub 2005 May 12.

2.

The role of MAPKs in B cell receptor-induced down-regulation of Egr-1 in immature B lymphoma cells.

Ke J, Gururajan M, Kumar A, Simmons A, Turcios L, Chelvarajan RL, Cohen DM, Wiest DL, Monroe JG, Bondada S.

J Biol Chem. 2006 Dec 29;281(52):39806-18. Epub 2006 Oct 24.

3.

Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.

Ke J, Chelvarajan RL, Sindhava V, Robertson DA, Lekakis L, Jennings CD, Bondada S.

Mol Cancer. 2009 Dec 31;8:132. doi: 10.1186/1476-4598-8-132.

5.

Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-kappa B, and p53.

Han SS, Chung ST, Robertson DA, Ranjan D, Bondada S.

Clin Immunol. 1999 Nov;93(2):152-61.

PMID:
10527691
6.

CpG oligodeoxynucleotides rescue BKS-2 immature B cell lymphoma from anti-IgM-mediated growth inhibition by up-regulation of egr-1.

Han SS, Chung ST, Robertson DA, Chelvarajan RL, Bondada S.

Int Immunol. 1999 Jun;11(6):871-9.

PMID:
10360960
7.

Requirement for JNK-dependent upregulation of BimL in anti-IgM-induced apoptosis in murine B lymphoma cell lines WEHI-231 and CH31.

Takada E, Hata K, Mizuguchi J.

Exp Cell Res. 2006 Nov 15;312(19):3728-38. Epub 2006 Aug 12.

PMID:
17007835
9.

[Hyperactivation of c-Jun NH(2)-terminal protein kinase contributes to the proliferation of B lymphoma cells].

Guo YY, Cui J, Hou CM, Wang QY, Wang J, Ma YF, Zhang JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):100-4. Chinese.

PMID:
21362231
10.

Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells.

Cui J, Wang Q, Wang J, Lv M, Zhu N, Li Y, Feng J, Shen B, Zhang J.

Mol Cancer Ther. 2009 Dec;8(12):3214-22. doi: 10.1158/1535-7163.MCT-09-0408.

12.

c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma.

Leventaki V, Drakos E, Karanikou M, Psatha K, Lin P, Schlette E, Eliopoulos A, Vassilakopoulos TP, Papadaki H, Patsouris E, Medeiros LJ, Rassidakis GZ.

Hum Pathol. 2014 Mar;45(3):565-72. doi: 10.1016/j.humpath.2013.10.024. Epub 2013 Oct 31.

PMID:
24457077
13.

JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis.

Alexaki VI, Javelaud D, Mauviel A.

Pigment Cell Melanoma Res. 2008 Aug;21(4):429-38. doi: 10.1111/j.1755-148X.2008.00466.x. Epub 2008 Jun 6.

PMID:
18541008
14.

p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis.

de Belle I, Huang RP, Fan Y, Liu C, Mercola D, Adamson ED.

Oncogene. 1999 Jun 17;18(24):3633-42.

16.

Role of Egr-1 gene expression in B cell receptor-induced apoptosis in an immature B cell lymphoma.

Muthukkumar S, Han SS, Rangnekar VM, Bondada S.

J Biol Chem. 1997 Oct 31;272(44):27987-93.

17.
18.

ABL-N-induced apoptosis in human breast cancer cells is partially mediated by c-Jun NH2-terminal kinase activation.

Liu B, Han M, Sun RH, Wang JJ, Zhang YP, Zhang DQ, Wen JK.

Breast Cancer Res. 2010;12(1):R9. doi: 10.1186/bcr2475. Epub 2010 Jan 25.

19.

Interference with nuclear factor kappa B and c-Jun NH2-terminal kinase signaling by TRAF6C small interfering RNA inhibits myeloma cell proliferation and enhances apoptosis.

Chen H, Li M, Campbell RA, Burkhardt K, Zhu D, Li SG, Lee HJ, Wang C, Zeng Z, Gordon MS, Bonavida B, Berenson JR.

Oncogene. 2006 Oct 19;25(49):6520-7. Epub 2006 May 15.

PMID:
16702955
20.

Supplemental Content

Support Center